Business Standard

Biocon rises on healthy Q3 earnings

Q3 net profit up 9% year-on-year at Rs 93 crore against an average analyst expectation of Rs 86 crore due to higher sales.

SI Reporter  |  Mumbai 

Biocon is trading higher by 4% to Rs 277 after reporting 9% year-on-year (yoy) rise in net profit at Rs 93 crore for the third quarter ended December 2012 (Q3) driven by period growth in different business verticals.

“Total sales of the company grew by 23% to Rs 635 crore from Rs 517 crore previous year,” said in a statement.

Analyst on an average had expected a net profit of Rs 86 crore and net sales of Rs 613 crore from the India’s largest biotechnology company by revenue.

“We have performed well across all our business verticals. We continue to gain market share for biosimilar insulins in global markets, which now accounts for a significant part of our business,” chairman and managing director said in a statement.

The company has received approval from the DCGI (Drugs Controller General of India) for our monoclonal antibody, Itolizumab, indicated for psoriasis. This is a significant milestone that enhances the value of this late-stage asset, added Kiran Mazumdar-Shaw.

The stock opened at Rs 268 and hit a high of Rs 278 on NSE. A combined 513,708 shares have already changed hands on the counter so far on both the exchanges.

 

RECOMMENDED FOR YOU

Biocon rises on healthy Q3 earnings

Q3 net profit up 9% year-on-year at Rs 93 crore against an average analyst expectation of Rs 86 crore due to higher sales.

Biocon is trading higher by 4% to Rs 277 after reporting 9% year-on-year (yoy) rise in net profit at Rs 93 crore for the third quarter ended December 2012 (Q3) driven by period growth in different business verticals.

Biocon is trading higher by 4% to Rs 277 after reporting 9% year-on-year (yoy) rise in net profit at Rs 93 crore for the third quarter ended December 2012 (Q3) driven by period growth in different business verticals.

“Total sales of the company grew by 23% to Rs 635 crore from Rs 517 crore previous year,” said in a statement.

Analyst on an average had expected a net profit of Rs 86 crore and net sales of Rs 613 crore from the India’s largest biotechnology company by revenue.

“We have performed well across all our business verticals. We continue to gain market share for biosimilar insulins in global markets, which now accounts for a significant part of our business,” chairman and managing director said in a statement.

The company has received approval from the DCGI (Drugs Controller General of India) for our monoclonal antibody, Itolizumab, indicated for psoriasis. This is a significant milestone that enhances the value of this late-stage asset, added Kiran Mazumdar-Shaw.

The stock opened at Rs 268 and hit a high of Rs 278 on NSE. A combined 513,708 shares have already changed hands on the counter so far on both the exchanges.

 

image

LIVE MARKET

BSE

  ( %)

NSE

  ( %)

Widgets Magazine

More News

STOCK WATCH

Company Price() Chg(%)
Ramkrishna Forg. 367.80 10.04
Idea Cellular 110.00 9.07
C P C L 157.20 8.41
Tata Motors 298.65 8.34
Bharti Infra. 384.55 8.29
> More on BSE Gainers
Company Price() Chg(%)
C P C L 157.15 8.64
Geojit BNP 32.10 8.63
Idea Cellular 109.65 8.40
Tata Motors 298.35 7.96
Bharti Infra. 384.10 7.89
> More on NSE Gainers
Company Price() Chg(%)
Bliss GVS Pharma 124.40 -19.97
B H E L 104.55 -13.13
Wockhardt 760.80 -13.09
Just Dial 417.45 -12.47
S C I 57.80 -9.97
> More on BSE Gainers
Company Price() Chg(%)
B H E L 104.45 -13.14
Wockhardt 762.10 -13.11
Just Dial 415.35 -12.54
SE Investments 165.55 -12.20
Cox & Kings 158.85 -10.25
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price